版本:
中国

BRIEF-Arch Biopartners' lead anti-bacterial drug candidate to enter investigator-sponsored Phase I human trial

April 13 Arch Biopartners Inc:

* Arch Biopartners' lead anti-bacterial drug candidate ab569 to enter investigator-sponsored Phase I human trial

* Arch Biopartners- Arch has initiated GMP manufacturing of AB569 drug product that is required for trial Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐